The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
Abstract Radioligand therapy is a targeted cancer treatment modality in which radioisotopes are utilized in the delivery of radiation at targeted cancer cells, with the goal of sparing normal cells. Prostate cancer is a well-known radiosensitive disease, historically treated with radioisotopes such...
Saved in:
| Main Authors: | Alexander Konopnicki, Michael Zaliznyak, Mathews Roy, Bagi Jana |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01680-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report
by: Yu-Yi Huang, et al.
Published: (2025-01-01) -
Improvement of End-of-Synthesis Radiochemical Purity of <sup>177</sup>Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization
by: Anton Larenkov, et al.
Published: (2024-11-01) -
Partial volume correction for Lu-177-PSMA SPECT
by: Yibin Liu, et al.
Published: (2024-11-01) -
Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in 177LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation
by: Sirwan Maroufpour, et al.
Published: (2024-12-01) -
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
by: Aaron R. Hansen, et al.
Published: (2025-01-01)